SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pfeiffer RF. A promising new technology for Parkinson's disease. Neurology 2005; 65: (Suppl. 1): S610.
  • 2
    Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998; 55: (Suppl. 1): 19.
  • 3
    Cawello W, Wolff HM, Meuling WJA, Horstmann R, Braun M. Transdermal administration of radiolabelled [14C]-rotigotine by a patch formulation. A mass balance trial. Clin Pharmacokinet 2007; 46: 8517.
  • 4
    Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man – administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009; 37: 205560.
  • 5
    Braun M, Cawello W, Andreas J-O, Boekens H, Horstmann R. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. J Clin Pharmacol 2009; 49: 104755.
  • 6
    Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009; 67: 20915.
  • 7
    The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 17218.
  • 8
    Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 2726.
  • 9
    LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system (PREFER Study). Neurology 2007; 68: 12627.
  • 10
    Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 51320.
  • 11
    Oertel WH, Beneš H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008; 9: 22839.
  • 12
    Trenkwalder C, Beneš H, Poewe W, Oertel WH, García-Borreguero D, de Weerd AW, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008; 7: 595604.
  • 13
    de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000; 54: (Suppl. 5): S213.
  • 14
    García-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006; 10: 15367.
  • 15
    La Manna G, Pizza F, Persici E, Baraldi O, Comai G, Cappuccilli ML, Centofanti F, Carretta E, Plazzi G, Coli L, Montagna P, Stefoni S. Restless legs syndrome enhances cardiovascular risk and mortality in patients with end-stage kidney disease undergoing long-term haemodialysis treatment. Nephrol Dial Transplant 2010; (Epub ahead of print).
  • 16
    Beck LH. Aging changes in renal function. In: Principles of Geriatric Medicine and Gerontology, 4th edn. eds Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG. New York: McGraw-Hill, 1999; 76776.
  • 17
    Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7: 110622.
  • 18
    U.S. Department of Health and Human Services, Food and Drug Administration guidance for industry. Pharmacokinetics in patients with impaired renal function – study design, data analysis, and impact on dosing and labelling. May 1998.
  • 19
    EMEA Guidance on the evaluation of the pharmacokinetics of medical products in patients with impaired renal function, CHMP/EWP/225/02, June 2004.
  • 20
    Araujo SM, de Bruin VM, Nepomuceno LA, Maximo ML, Daher EF, Correia Ferrer DP, de Bruin PF. Restless legs syndrome in end-stage renal disease: clinical characteristics and associated comorbidities. Sleep Med 2010; 11: 78590.
  • 21
    Bennett JP Jr, Piercey MF. Pramipexole: a new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 1999; 163: 2531.
  • 22
    Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 24354.
  • 23
    Requip® (ropinirole tablets): GlaxoSmithKline prescribing information. Available at http://us.gsk.com/products/assets/us_requip.pdf (last accessed 22 Jul 2011).
  • 24
    Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003; 42: 63345.
  • 25
    Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41: 261309.